
Sai Life Sciences IPO
- Issue price
- ₹549
- Listing price
- ₹650
- +18.40%
- Current price
- ₹1,928.8
- +251.33%
- Subscribed
- 10.27x
- Issue size
- ₹3,042.62 Cr
- Listed on
- 18 Dec 2024
IPO timeline
- Opens11 DecWed
- Closes13 DecFri
- Allotment16 DecMon
- Refunds17 DecTue
- Demat credit17 DecTue
- Listing18 DecWed
Issue details
- Price band
- ₹522 – ₹549 per share
- Issue size
- ₹3,042.62 Cr
- Fresh issue
- Not available
- Offer for sale
- Not available
- Issue type
- Fresh capital cum OFS
- Face value
- ₹1 per share
- Lot size
- 27 shares
- Minimum investment
- ₹14,823
- Listing on
- BSE, NSE
- Exchange code
- SAILIFE · 544306
This issue combines a fresh issue and an offer for sale. The amounts for each part are not available in our data; see the offer document for the split.
Lot size and investment
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 27 | ₹14,823 |
| Retail (Max) | 13 | 351 | ₹1,92,699 |
| S-HNI (Min) | 14 | 378 | ₹2,07,522 |
| B-HNI (Min) | 68 | 1,836 | ₹10,07,964 |
Reservation
- QIB
- 2,77,10,560 shares (50.00% of the Offer)
- NII
- 83,13,169 shares (15.00% of the Offer)
- Retail
- 1,93,97,394 shares (35.00% of the Offer)
Allotment status
The allotment for this IPO is final. Check whether you received shares on the registrar's website using your PAN, application number or demat account (DP / Client ID).
Check allotment on KFin Technologies- 1Open the registrar's allotment page and select this IPO from the list.
- 2Enter your PAN, application number or DP / Client ID.
- 3Submit to see the number of shares allotted, if any.
- Basis of allotment
- 16 Dec 2024
- Refunds initiated
- 17 Dec 2024
- Shares credited to demat
- 17 Dec 2024
- Listing
- 18 Dec 2024
Grey market premium (GMP)
- Current GMP
- ₹70
- +13.00%
- Estimated listing price
- ₹619
- Issue price ₹549
- Highest
- ₹70
- 17 Dec
- Lowest
- ₹27
- 13 Dec
GMP by day (₹ per share)
Day-wise GMP table
| Date | GMP | Premium | Est. listing |
|---|---|---|---|
| 17 Dec 2024 | ₹70 | +13.00% | ₹619 |
| 16 Dec 2024 | ₹42 | +8.00% | ₹591 |
| 14 Dec 2024 | ₹38 | +7.00% | ₹587 |
| 13 Dec 2024 | ₹27 | +5.00% | ₹576 |
| 12 Dec 2024 | ₹38 | +7.00% | ₹587 |
| 11 Dec 2024 | ₹33 | +6.00% | ₹582 |
| 10 Dec 2024 | ₹35 | +6.00% | ₹584 |
| 9 Dec 2024 | ₹30 | +5.00% | ₹579 |
| 7 Dec 2024 | ₹30 | +5.00% | ₹579 |
- Kostak rate
- ₹0
GMP is an unofficial indicator from an unregulated market. It is shown for information only and is not a prediction of the listing price or a recommendation to apply.
Subscription status
- QIB29.78x
- NII (HNI)4.99x
- Retail1.39x
Financials
- P/E Ratio
- 203.82
- EPS (₹)
- 2.69
- RoE
- 11.79%
- RoCE
- 15.96%
- RoNW
- 8.13%
- PAT Margin
- 5.65%
- NAV (₹)
- 53.94
Separate pre- and post-issue P/E are not available for this IPO; the P/E shown is as disclosed for the issue.
| Period ended | 30 Sep 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|---|
| Assets | 2,476.78 | 2,275.14 | 2,186.65 | 2,164.23 |
| Total Income | 693.35 | 1,494.27 | 1,245.11 | 897.74 |
| Profit After Tax | 28.01 | 82.81 | 9.99 | 6.23 |
| NET Worth | 1,044.75 | 974.34 | 887.29 | 877.76 |
| Total Borrowing | 764.49 | 710.16 | 699.23 | 751.32 |
Peer comparison
| Company | Issue size | P/E | RoNW | PAT margin | Subscribed | Listing gain |
|---|---|---|---|---|---|---|
| Sai Life Sciences This IPO | ₹3,042.62 Cr | 203.82 | 8.13% | 5.65% | 10.27x | +18.40% |
| Anthem Biosciences Mainboard · listed 21 Jul 2025 | ₹3,395 Cr | 70.62 | 20.82% | 23.38% | 67.42x | +26.85% |
| Inventurus Knowledge Solutions Mainboard · listed 19 Dec 2024 | ₹2,497.92 Cr | 54.66 | 32% | 20.38% | 52.68x | +42.96% |
| Sagility India Mainboard · listed 12 Nov 2024 | ₹2,106.4 Cr | 61.52 | 0.29% | 11.83% | 3.2x | +3.53% |
| Akums Drugs & Pharmaceuticals Mainboard · listed 6 Aug 2024 | ₹1,856.74 Cr | 13580 | -0.57% | 0.02% | 63.44x | +6.77% |
| Indegene Mainboard · listed 13 May 2024 | ₹1,841.76 Cr | 33.53 | 18.23% | 12.62% | 70.3x | +44.91% |
| Symbiotec Pharmalab Mainboard · listed 1 Sep 2026 | ₹1,757 Cr | 56.81 | 9.48% | 12.60% | 71.26x | 0.00% |
Peers are other recent IPOs from the same industry, closest in issue size. Ratios are as disclosed at the time of each issue. This is not the listed-peer table from the offer document.
IPO objectives
How Sai Life Sciences plans to use the money raised, as stated in the offer document.
- Repayment/prepayment, in full or part, of all or certain outstanding borrowings availed by our Company₹720 Cr
- General corporate purposes₹198.98 Cr
About Sai Life Sciences
Sai Life Sciences Limited was incorporated on 25 January 1999. It is a pure-play, fully integrated, innovator-focused contract research, development and manufacturing organisation (CRDMO). It provides end-to-end services across drug discovery, development and manufacturing for small molecule new chemical entities, serving global pharmaceutical innovators and biotech firms. It has both discovery and contract research and CMC and CDMO capabilities. Its promoters include Kanumuri Ranga Raju, Krishnam Raju Kanumuri, Kanumuri Mytrey and Sai Quest Syn. The IPO was Rs 3,042.62 crore, with Rs 950.00 crore of fresh issue and Rs 2,092.62 crore of offer for sale, mostly by TPG and HBM investors, with Sai Quest Syn also selling. Fresh money was mainly planned for repaying borrowings.
Strengths
- Total income rose from Rs 897.74 crore in FY2022 to Rs 1,494.27 crore in FY2024.
- Profit after tax rose from Rs 9.99 crore in FY2023 to Rs 82.81 crore in FY2024.
- Rs 950.00 crore of the issue was fresh capital, mostly for repaying debt.
- It serves global drug innovators across discovery, development and manufacturing, and has operated since 1999.
- Net worth was Rs 1,044.75 crore on 30 September 2024.
Risks
- The pre-issue P/E was 126.42 at the upper band of Rs 549, based on EPS of Rs 4.34.
- Margins are thin, and the source puts the PAT margin at 5.65%.
- Total borrowing was Rs 764.49 crore on 30 September 2024.
- CRDMO income depends on client pipelines and global biotech funding, and Rs 2,092.62 crore of the issue was offer for sale.
- Promoters held only 41.82% before the issue and 35.24% after it.
Promoters and shareholding
Kanumuri Ranga Raju, Krishnam Raju Kanumuri, Kanumuri Mytrey, Sai Quest Syn Pvt.Ltd, Sunflower Partners, Lily Partners, Marigold Partners and Tulip Partners
- Promoter holding, pre-issue
- 41.82%
- Promoter holding, post-issue
- 35.24%
Registrar, lead managers and documents
Lead managers
Documents
Sai Life Sciences IPO: common questions
1.When does the Sai Life Sciences IPO open and close?
The Sai Life Sciences IPO opens on 11 Dec 2024 and closes on 13 Dec 2024.
2.What is the price band of the Sai Life Sciences IPO?
The price band is ₹522 – ₹549 per share, with a lot size of 27 shares and a minimum investment of ₹14,823.
3.What is the size of the Sai Life Sciences IPO?
The issue size is ₹3,042.62 Cr (Fresh capital cum OFS).
4.What is the GMP of the Sai Life Sciences IPO?
The last reported grey market premium is ₹70 per share as of 17 Dec 2024, 12:00 PM IST. GMP is unofficial and changes frequently.
5.When is the Sai Life Sciences IPO allotment?
The basis of allotment is expected on 16 Dec 2024. Allotment status can be checked with the registrar, KFin Technologies Limited.
6.When will the Sai Life Sciences IPO list?
The shares listed on 18 Dec 2024 on BSE, NSE.
7.Who is the lead manager of the Sai Life Sciences IPO?
The book running lead managers are Kotak Mahindra Capital Company Limited, Jefferies India Private Limited, IIFL Capital Services Limited, Morgan Stanley India Co. Pvt. Ltd, and the registrar is KFin Technologies Limited.
8.What will the money raised in the Sai Life Sciences IPO be used for?
As stated in the offer document, the proceeds are for: Repayment/prepayment, in full or part, of all or certain outstanding borrowings availed by our Company; General corporate purposes.
9.How can my company launch an IPO like Sai Life Sciences?
Start with an IPO readiness assessment: eligibility for the Main Board, audited financials, governance, conversion to a public limited company and an indicative valuation. Be IPO Ready advises promoters through each step, from readiness to listing day.
For business owners
Your company could be the next listing
Businesses like these raise growth capital on the public markets every week. Tell us about yours and our advisors will tell you, plainly, whether an IPO is within reach and what it would take.
- Eligibility check against NSE Emerge, BSE SME and Main Board norms
- Indicative valuation and issue size for your business
- A clear timeline from readiness to listing day
Check if your business can list
Fill in the eligibility form and get an assessment of where you stand. It takes about five minutes.
Prefer to talk? Call +91 92130 20393